The company, along with its subsidiary NTPC Green Energy, has entered into multiple MoUs with the Madhya Pradesh government ...

India's CRDMO sector is set to reach USD 22-25 billion by 2035, driven by cost advantages and rapid project startups, according to a BCG and IPSO report. India is emerging as a preferred outsourcing ...

India's CRDMO sector, projected to hit $22-25 billion by 2035, is rapidly expanding due to cost advantages and quick startup ...

Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...

Discover the top female billionaires in India reshaping business and wealth distribution. Learn about their contributions and ...

If successful, Mankind’s drug would be the first oral small-molecule alternative, offering a pill-based treatment.

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Anand Mahindra underlines the need for a healthier population to achieve Indias 2047 vision, responding to PM Modis call to ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune ...